1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Illumacell Inc. is currently managing 1 pending office action. This matter is assigned to 1 distinct examiner working within 1 distinct art unit. The prosecution footprint is limited to this single pending action, which simplifies the administrative burden of tracking multiple deadlines. Practitioners can focus their resources on the specific requirements of the assigned examiner without the need to coordinate across multiple technical areas. This singular focus suggests that the company is prioritizing a specific technical advancement.
KASZTEJNA, MATTHEW JOHN is the busiest examiner for the company, as he is responsible for 1 pending office action. Because there is only 1 distinct examiner and 1 distinct art unit involved, there is no risk of inconsistent examiner behavior across the portfolio. This singular engagement allows for a direct and specialized approach to the current prosecution. The absence of other pending matters suggests that the company's current patent strategy is highly focused on this individual application. Practitioners should treat this 1 pending office action as a critical component of the company's intellectual property strategy. The outcome of this matter will define the company's immediate patent position and allow for a more efficient use of legal resources.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASZTEJNA, MATTHEW JOHN | 1 | 64.5% | +13.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18509046 | DEVICE FOR PHOTODYNAMICAL THERAPY OF CANCER | KASZTEJNA, MATTHEW JOHN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18509046 | DEVICE FOR PHOTODYNAMICAL THERAPY OF CANCER | KASZTEJNA, MATTHEW JOHN | — |
| Art Unit | Apps |
|---|---|
| 3993 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18509046 | DEVICE FOR PHOTODYNAMICAL THERAPY OF CANCER | KASZTEJNA, MATTHEW JOHN | 3993 | §103§112Other | Non-Final OA | — | Pending | Nov 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIllumacell Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Matthew John Kasztejna has the most, with 1 of Illumacell Inc.'s pending office actions.
